araag2/HINT huggingface dataset:
Clinical trial NCT00003624 (phase 2, status: terminated)
Conditions: cervical cancer, endometrial cancer, fallopian tube cancer, neurotoxicity, ovarian cancer, primary peritoneal cavity cancer, sarcoma
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90, N85.00, N85.01, N85.02, N99.85, C57.00, C57.01, C57.02, G92.00, G92.01, G92.02, G92.03, G92.04, G92.05, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: amifostine trihydrate, cisplatin, paclitaxel
SMILES: NCCCNCCSP(O)(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Ovarian, primary peritoneal, cervical, or fallopian tube
        carcinoma, uterine sarcoma, or endometrial adenocarcinoma for which the proposed treatment
        is cisplatin plus paclitaxel Must be ineligible for a higher priority GOG protocol

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-3 Life expectancy:
        Not specified Hematopoietic: WBC at least 3,000/mm3 Granulocyte count at least 1,500/mm3
        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper
        limit of normal (ULN) AST and alkaline phosphatase no greater than 3 times ULN Renal:
        Creatinine no greater than 2.0 mg/dL Cardiovascular: No hypertension for which medication
        cannot be discontinued for 24 hours through the day of each chemotherapy treatment Other:
        No history of neuropathy (e.g., diabetic neuropathy) No significant infection Prior
        malignancy allowed if disease free for at least 12 months No physical disabilities
        precluding vibration perception threshold testing of the upper and lower extremity (e.g.,
        amputation, paraplegia)

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy for ovarian, primary peritoneal, or fallopian tube carcinoma, uterine sarcoma,
        or endometrial adenocarcinoma Endocrine therapy: Not specified Radiotherapy: No prior
        radiotherapy except for cervical carcinoma Surgery: Not specified
Clinical trial NCT00160511 (phase 2, status: completed)
Conditions: neuralgia, postherpetic
ICD codes: B02.22
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  male or female outpatient greater than or equal to 18 years of age.

          -  suffering presently from neuralgia, which has been present for at least 3 months since
             healing of acute herpes zoster skin rash.

          -  PHN pain at entry into the study must meet the following criteria: a VAS of at least
             40 mm at visit 2 (to assess pain intensity during the past week) and with an average
             daily score of at least 4 on the PIS during the baseline period as evaluated on a
             minimum of 4 days.

          -  an estimated creatinine clearance of at least 50 ml/min.

        Exclusion Criteria:

          -  receiving professional psychological support (such as cognitive behavioral therapy)
             currently or within 2 weeks prior to visit 1 specifically for coping with PHN.

          -  previous neurolytic or neurosurgical therapy for PHN, at any time in the subject's
             history or treatment with TENS (transelectroneuro stimulation) currently or within the
             past 2 weeks.

          -  known co-existent source of pain or painful peripheral neuropathy.

          -  known significant neurological disorder other than the study disease or a condition
             which can mimic stroke with distal neurological deficit (amyotrophy, radiculopathy,
             history of TIAs, multiple sclerosis, or any amputations).

          -  conditions known to be associated with immunosuppressive states.

          -  clinically significant major depression defined as a Beck Depression Inventory Score >
             21 at selection including those with a history of Bipolar Disorder.
Clinical trial NCT00005997 (phase 2, status: terminated)
Conditions: extrahepatic bile duct cancer, gallbladder cancer, liver cancer
ICD codes: C24.0, D13.5, C23, D37.6, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: becatecarin
SMILES: CCN(CC)CCN1C(=O)C2=C(C1=O)C1=C(N([C@@H]3O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]3O)C3=C(Cl)C=CC=C13)C1=C2C2=C(N1)C(Cl)=CC=C2
Reason stopped: 
    slow accrual for cohort ii
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of advanced hepatobiliary carcinoma not amenable to conventional surgery

               -  Gall bladder carcinoma

               -  Cholangiocarcinoma

               -  Carcinoma of the ampulla

               -  Hepatocellular carcinoma (eligible for cohort II only)

          -  Measurable disease

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 12 weeks

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic:

          -  Bilirubin less than 3 mg/dL

               -  Cohort I (closed to accrual as of 11/1/03)

                    -  Bilirubin no greater than 1.5 mg/dL

                    -  AST no greater than 2.5 times upper limit of normal (ULN)

               -  Cohort II

                    -  Bilirubin greater than 1.5 mg/dL and less than 3 mg/dL OR

                    -  Bilirubin no greater 1.5 mg/dL AND AST greater than 2.5 times ULN

        Renal:

          -  Creatinine normal OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No New York Heart Association class III or IV heart disease

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for cholangiocarcinoma or hepatobiliary carcinoma

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No concurrent combination antiviral therapy for HIV-positive patients
Clinical trial NCT01545518 (phase 2, status: terminated)
Conditions: epilepsy, cryptogenic, epilepsy, partial, seizure disorder, autoimmune diseases, nervous system, limbic encephalitis
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: ivig
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
Reason stopped: 
    futility criteria, unable for phase 2 of study, & phase 1 was terminated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of uncontrolled epilepsy with at least two seizures a month for three
             consecutive months.

          -  Age 18 to 50.

          -  Clinical semiology or electroencephalogram (EEG) consistent with partial onset
             epilepsy.

          -  Refractory to an adequate trial of two or more main-line anti-epileptic drugs.

          -  Ability to keep a seizure diary.

          -  Normal brain magnetic resonance imaging (MRI) - 3 Tesla, seizure protocol; with the
             exception of hippocampal sclerosis

        Exclusion Criteria:

          -  History of severe prematurity or neonatal distress, febrile seizures, moderate or
             sever traumatic brain injury, stroke, brain tumor, meningitis, encephalitis,
             neurocutaneous syndromes, or intracranial metal objects.

          -  Evidence of psychogenic epilepsy.

          -  History of convulsive status epilepticus.

          -  History of primary generalized epilepsy in a first degree relative.

          -  Known serious medical illness.
Clinical trial NCT01022541 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven diagnosis of colorectal adenocarcinoma

          -  Metastatic disease present in the liver only.

          -  Absence of extrahepatic metastases excluded by CT chest, abdomen and pelvis.
             Indeterminate CT findings may require verification by FDG-PET scanning.

          -  Liver-only metastases determined to be unresectable at presentation on a pre-treatment
             liver MRI with an appropriate liver specific contrast (eg. TESLA) by a specialist
             multidisciplinary team (consisting of medical oncologist, hepatic surgeon and
             radiologist). Guidelines for determining unresectability include:

          -  presence of >4 metastases;

          -  size >5cm;

          -  location and distribution of metastatic disease within the liver unsuitable for
             resection with clear margins (eg. Involvement of both lobes of liver; invasion of
             intrahepatic vascular structures);

          -  extent of liver involvement precluding resection with adequate post-resection residual
             liver parenchyma volume for viable liver function in the immediate post-operative
             period;

          -  inability to retain adequate vascular in flow and out flow to maintain viable liver
             function.

          -  No previous treatment for metastatic colorectal cancer, including chemotherapy,
             targeted or experimental therapies (e.g. anti-VEGF or anti-EGFR), radiotherapy to the
             liver, or surgery or radiofrequency ablation to liver metastases.

          -  Feasibility of surgery with curative intent:

          -  If the primary colorectal tumour is in situ, the primary tumour must also be
             resectable with curative intent

          -  Patients presenting with liver metastases only relapse after initially curative
             resection of their primary colorectal cancer followed by treatment with adjuvant
             chemotherapy may not be entered into the study if the relapse has occurred within 12
             months of completion of adjuvant treatment

          -  Adequate medical fitness to undergo neoadjuvant treatment and surgery with curative
             intent (hepatectomy +/- resection of primary tumour, if required)

          -  Absence of pre-existing liver dysfunction of Childs Pugh Grade B or greater. Patients
             who are suspected of having pre-existing liver dysfunction due to clinical,
             biochemical or radiological findings, should have significant liver disease excluded
             by a liver biopsy prior to study entry.
Clinical trial NCT00619190 (phase 2, status: completed)
Conditions: autistic disorder, asperger syndrome, autism spectrum disorder
ICD codes: F84.0, F84.5, Z16.12
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be between 30 months and 17 years 11 months, male or female, of any
             ethnicity and of any cognitive level

          -  Meet criteria for diagnosis of autism, Asperger's Disorder or Pervasive Developmental
             Order NOS (i.e. an autism spectrum disorder) based on clinical evaluation and either
             the Autism Diagnostic Interview - Revised (ADI-R) or the Autism Diagnostic Observation
             Scale (ADOS)

          -  Have a guardian who is able and willing to give written informed consent

          -  If competent, subject able and willing to give written assent for their own
             participation

          -  If on anticonvulsants, subject have been seizure-free and on a stable anticonvulsant
             regimen for at least 6 months

          -  Subjects may receive other nonpharmacologic treatment including dietary treatments

        Exclusion Criteria:

          -  Diagnosis of Rett's syndrome or Child Disintegrative Disorder

          -  Taken psychotropic medications other than clonidine or diphenhydramine within 2 weeks

          -  Previous trial of aripiprazole

          -  Pregnant or nursing

          -  Epilepsy or another significant chronic medical illness
Clinical trial NCT00659230 (phase 2, status: completed)
Conditions: posttraumatic stress disorder
ICD codes: F43.10, F43.11, F43.12
Drugs: nepicastat, placebo
SMILES: NCC1=CNC(=S)N1[C@H]1CCC2=C(C1)C=C(F)C=C2F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Patient understands the risks and benefits and agrees to visit frequency and
             procedures

          -  Male or female

          -  Any race or ethnic origin

          -  Served in OIF/OEF or Afghanistan conflicts or other Southwest Asia conditions

          -  Currently Active Duty, National Guard, Reservist, Veteran, and/or Retired Military

          -  Diagnosis of PTSD (by MINI (Mini International Neuropsychiatric Interview) and CAPS-DX
             (Clinician Administered PTSD scale- Diagnostic Form) using Rule of Fours and total
             CAPS-DX score of 45)

          -  No substance use disorders in the previous 2 weeks and no substance dependence
             disorders in the past 4 weeks (except for nicotine and caffeine)

          -  Free of psychotropic medication for 2 weeks prior to randomization

          -  Physical and laboratory panel are within normal limits or not clinically significant

          -  Women of childbearing potential must be using medically-approved methods of birth
             control

          -  ≥19 to 65 years of age

        Exclusion Criteria:

          -  Lifetime history of bipolar I, schizophrenia, schizoaffective or cognitive disorders

          -  Actively considering plans of suicide or homicide

          -  Psychotic symptoms that in the investigator's opinion impair the patient's ability to
             give informed consent or make it unsafe for patient to be maintained without a
             neuroleptic

          -  Unstable general medical conditions or a contraindication to the use of nepicastat

          -  Women planning to become pregnant or breastfeed during the study

          -  Current or pending incarceration

          -  Terminal Illness
Clinical trial NCT01092143 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: bi671800, bi671800, bi 671800, fluticasone placebo, fluticasone placebo, fluticasone placebo, fluticasone placebo, fluticasone, bi 671800 placebo, bi 671800 placebo
SMILES: CN(C)C1=NC(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)=NC(N(C)C)=C1CC(O)=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Signed informed consent consistent with ICH-GCP

          2. Three month history of reversible (12% with 200 mL) asthma (according to GINA) with
             following spirometry at randomization: FEV1 60%-85%.

          3. No ICS previous 3 months prior to screening.

          4. Diagnosis of asthma prior to 40 years.

          5. ACQ at least 1.5 at randomization.

          6. Male or female, 18 to 65 years.

          7. Non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine
             screen.

          8. Able to perform PFT

        Exclusion criteria:

          1. Significant diseases other than asthma or allergic rhinitis.

          2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.

          3. Hospitalizations for asthma or asthma related intubation within 3 months.

          4. Uncontrolled asthma.

          5. Respiratory tract infection or exacerbation within 4 weeks.

          6. FEV1 less than 40%, more than 12 puffs of SABA on more than two consecutive days or
             asthma exacerbation during the run-in period.

          7. Participation in another interventional study.

          8. Pregnant or nursing women.

          9. Women of child bearing potential nor using appropriate methods of birth control as
             defined by protocol
Clinical trial NCT00230126 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Must have histologically or cytologically confirmed stage IIIB or IV NSCLC treated
             with 1-2 platinum- or taxane-containing regimens

          -  Measurable disease

          -  May have had prior surgery & external beam radiation

          -  African American

          -  18 years or older

        Exclusion Criteria:

          -  Known brain mets

          -  Prior treatment with EGFR targeting therapies

          -  Pregnant/lactating women
Clinical trial NCT00618007 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: pf-00734200 30 mg qd, pf-00734200 20 mg qd, placebo
SMILES: [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

        Exclusion Criteria:

        Type 1 or secondary forms of diabetes Currently using insulin
Clinical trial NCT00594945 (phase 2, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: clonazepam
SMILES: [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of refractory epilepsy

          -  No Nasal conditions that would preclude the use of intranasal product

        Exclusion Criteria:

          -  Subject with a clinical significant unstable medical abnormality

          -  Subject currently or regularly taking Clonazepam
Clinical trial NCT00537095 (phase 2, status: active, not recruiting)
Conditions: thyroid neoplasms
ICD codes: C73, D34, D44.0, Z85.850
Drugs: vandetanib
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Previously confirmed histological diagnosis of locally advanced or metastatic
             papillary or follicular thyroid carcinoma, without anaplastic component. Tumor sample
             available for centralized exploratory analysis.

          -  Presence of one or more measurable lesions at least 1 cm in the longest diameter by
             spiral CT scan or 2 cm with conventional techniques.

          -  Progressive disease following RAI131 or patient unsuitable for RAI131 after surgery.

          -  Serum TSH<0.5mU/L.

        Exclusion Criteria:

          -  Major surgery within 4 weeks before randomization.

          -  Prior chemotherapy within the last 4 weeks prior to randomization.

          -  RAI131 therapy within 3 months in patients with radioiodine uptake.

          -  Radiation therapy within the last 4 weeks prior to randomization (with the exception
             of palliative radiotherapy).

          -  Serum bilirubin >1.5 x the upper limit of reference range (ULRR).

          -  Creatinine clearance < 30 ml/min (calculated by Cockcroft-Gault formula).

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline
             phosphatase (ALP) greater than 2.5 × ULRR, or greater than 5.0 × ULRR if judged by the
             investigator to be related to liver metastases.

          -  Clinically significant cardiovascular event (eg myocardial infarction), superior vena
             cava [SVC] syndrome, New York Heart Association [NYHA] classification of heart failure
             >II within 3 months before entry, or presence of cardiac disease that in the opinion
             of the Investigator increases the risk of ventricular arrhythmia.

          -  History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy,
             trigeminy, ventricular tachycardia or uncontrolled atrial fibrillation), which is
             symptomatic or requires treatment (CTCAE grade 3), , or asymptomatic sustained
             ventricular tachycardia. Subjects with atrial fibrillation controlled by medication
             are permitted.

          -  Congenital long QT syndrome or 1st degree relative with unexplained sudden death under
             40 years of age.